Diabetes mellitus en pacientes con enfermedad de Alzheimer: descripción clínica y correlación con el genotipo APOE en una muestra de población del departamento de Antioquia, Colombia
Resumen
Introducción. La enfermedad de Alzheimer es compleja y afecta, aproximadamente, a 20 millones de personas en todo el mundo. Muchas variables parecen aumentar el riesgo de desarrollar esta alteración neurológica. Entre los factores de riesgo, se ha demostrado ampliamente que la diabetes mellitus y la isoforma ε4 del gen APOE tienen incidencia positiva en el desarrollo de la enfermedad. Se reporta un estudio en el cual se investigó la posible correlación entre APOE, diabetes mellitus yla enfermedad de Alzheimer, en un grupo específico de pacientes del departamento de Antioquia, Colombia.
Objetivo. Determinar si existe una correlación entre APOE, diabetes mellitus y la enfermedad de Alzheimer, en un grupo de pacientes de Antioquia, Colombia.
Materiales y métodos. Se buscaron y analizaron las historias clínicas de los pacientes con diagnóstico de enfermedad de Alzheimer. Se seleccionaron aquellos que cumplían los criterios de inclusión. Se utilizaron métodos comercialmente disponibles para confirmar la presencia de diabetes mellitus. La genotipificación de APOE se hizo con un método basado en la PCR y la digestión con enzimas de restricción, en muestras de todos los participantes en el estudio.
Resultados. En este estudio se analizan 43 casos de enfermedad de Alzheimer y 43 individuos sanos controles, pareados por edad y sexo. Las enfermedades concomitantes no neurológicas más comunes fueron: hipertensión arterial, infarto agudo del miocardio, enfermedad pulmonar obstructiva crónica e hipotiroidismo.Conclusiones. De las diferentes variables investigadas, dos arrojaron resultados concluyentes: i) la presencia de la enfermedad de Alzheimer es más frecuente en pacientes con diabetes mellitus, y 2) no se encontró correlación entre la enfermedad de Alzheimer de inicio tardío esporádico y el genotipo de APOE. Es importante indicar que debe llevarse a cabo un estudio con un tamaño de población mayor, para determinar cualquier posible correlación o inferencia con el genotipo de APOE.
doi: http://dx.doi.org/10.7705/biomedica.v32i2.579
Descargas
Referencias bibliográficas
Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819-28. doi: http://dx.doi.org/10.1016/S1474-4422(11)70072-2
Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010;6:98-103. doi: http://dx.doi.org/10.1016/j.jalz.2010.01.010
WHO. Atlas: Country resources for neurological disorders. World Health Organization and World Federation of Neurology. Geneva: WHO; 2004. p. 52.
Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741-66. PMid:11274343
Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med. 1999;340:1970-80. doi: http://dx.doi.org/10.1056/NEJM199906243402507
Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment. BMC Neurol. 2002; 2:9. doi: http://dx.doi.org/10.1186/1471-2377-2-9
Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, et al. Assessment of endothelial function in Alzheimer’s disease: Is Alzheimer’s disease a vascular disease? J Am Geriatr Soc. 2007;55:1613-7. doi: http://dx.doi.org/10.1111/j.1532-5415.2007.01378.x
Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, et al. Gene delivery of human apolipoprotein E alters brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2005;102:1211-6. doi: http://dx.doi.org/10.1073/pnas.0409072102
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition. Washington, DC: APA; 2000. p. 157.
Dickson DW. Neuropathological diagnosis of Alzheimer’s disease: A perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997;18(Suppl.):S21-6. doi: http://dx.doi.org/10.1016/S0197-4580(97)00065-1
Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med. 2010;4:51-63. doi: http://dx.doi.org/10.2217/bmm.09.83
Alzheimer’s Association, Thies W, Bleiler L. Alzheimer’s disease facts and figures. Alzheimers Dement. 2011;7:208-44. doi: http://dx.doi.org/10.1016/j.jalz.2011.02.004
Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer’s disease: Relation to apolipoprotein E polymorphism. Neurology. 1996;46:413-9. doi: http://dx.doi.org/10.1212/WNL.46.2.413
Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: The Hisayama Study. Neurology. 1995;45:1161-8. doi: http://dx.doi.org/10.1212/WNL.45.6.1161
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvensen GS, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-81. doi: http://dx.doi.org/10.1073/pnas.90.5.1977
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl.1):S62-7. doi: http://dx.doi.org/10.2337/dc09-S062
Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65-85. doi: http://dx.doi.org/10.1016/S0168-8227(01)00365-5
Ryden L, Standl E, Bartnik M, van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes,pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136. PMid:17220161
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40. doi: http://dx.doi.org/10.1016/S0140-6736(11)60679-X
Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8-13. doi: http://dx.doi.org/10.2337/dc06-1414
WHO. Diabetes. Geneve: WHO; 2011. Accessed: September 15, 2011. Disponible en: http://www.who.int/mediacentre/factsheets/fs312/en/index.html
Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002;18(Suppl.3):S27-31. doi: http://dx.doi.org/10.1002/dmrr.280
Alzheimer’s Disease Association. Standards of medical care in diabetes -2011. Diabetes Care. 2011;34(Suppl.1):S11-61. doi: http://dx.doi.org/10.2337/dc11-S011
Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology. 2011;77:1126-34. doi: http://dx.doi.org/10.1212/WNL.0b013e31822f0435
Peila R, Rodríguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-62. doi: http://dx.doi.org/10.2337/diabetes.51.4.1256
Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hänninen T, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension. 1993;22:771-9. doi: http://dx.doi.org/10.1161/01.HYP.22.5.771
Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol. 1997;145:301-8. doi: http://dx.doi.org/10.1093/oxfordjournals.aje.a009106
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937-42.
doi: http://dx.doi.org/10.1212/WNL.53.9.1937
Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry. 2006;11:721-36. doi: http://dx.doi.org/10.1038/sj.mp.4001854
Messier C. Diabetes, Alzheimer’s disease and apolipoprotein genotype. Exp Gerontol. 2003;38:941-6. doi: http://dx.doi.org/10.1016/S0531-5565(03)00153-0
Mahley RW, Huang Y. Apolipoprotein (apo) E4 and Alzheimer’s disease: Unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurol Scand Suppl. 2006;185:8-14. doi: http://dx.doi.org/10.1111/j.1600-0404.2006.00679.x
Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest. 2006;116:1226-9. doi: http://dx.doi.org/10.1172/JCI28632
Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103:5644-51. doi: http://dx.doi.org/10.1073/pnas.0600549103
Powell DS, Maksoud H, Charge SB, Moffitt JH, Desai M, Da Silva Fihlo RL, et al. Apolipoprotein E genotype, islet amyloid deposition and severity of type 2 diabetes. Diabetes Res Clin Pract. 2003;60:105-10. doi: http://dx.doi.org/10.1016/S0168-8227(02)00281-4
Edland SD. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease. J Mol Neurosci. 2004;23:213-7. doi: http://dx.doi.org/10.1385/JMN:23:3:213
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921-3. doi: http://dx.doi.org/10.1126/science.8346443
Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease. Biol Psychiatry. 1999;45:422-5. doi: http://dx.doi.org/10.1016/S0006-3223(98)00041-9
Forero DA, Pinzón J, Arboleda GH, Yunis JJ, Álvarez C, Cataño N, et al. Analysis of common polymorphisms in angiotensin-converting enzyme and apolipoprotein E genes and human longevity in Colombia. Arch Med Res. 2006;37:890-4. doi: http://dx.doi.org/10.1016/j.arcmed.2006.04.001
Callas N, Poveda E, Baracaldo C, Hernández P, Castillo C, Guerra M. Polimorfismo genético de la apolipoproteína E en un grupo de escolares del centro-oriente colombiano: comparación con las concentraciones plasmáticas de lípidos y apolipoproteínas. Biomédica. 2007;27:526-36. PMid:18320120
Hernández-Fonseca JP, Rincón J, Pedreanez A, Viera N, Arcaya JL, Carrizo E, et al. Structural and ultrastructural analysis of cerebral cortex, cerebellum, and hypothalamus from diabetic rats. Exp Diabetes Res. 2009;2009:329632.
Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, et al. Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol. 1998;153:1149-55. doi: http://dx.doi.org/10.1016/S0002-9440(10)65659-3
Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-34. doi: http://dx.doi.org/10.1146/annurev.med.46.1.223
Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A. 1994;91:7787-91. doi: http://dx.doi.org/10.1073/pnas.91.16.7787
Klein JP, Waxman SG. The brain in diabetes: Molecular changes in neurons and their implications for end-organ damage. Lancet Neurol. 2003;2:548-54. doi: http://dx.doi.org/10.1016/S1474-4422(03)00503-9
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-47. doi: http://dx.doi.org/10.1136/jnnp.66.2.137
Nitsch RM. From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer’s disease. Neurodegeneration. 1996;5:477-82. doi: http://dx.doi.org/10.1006/neur.1996.0066
Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol. 2009;66:300-5.
doi: http://dx.doi.org/10.1001/archneurol.2009.27
Kameyama M, Fushimi H, Udaka F. Diabetes mellitus and cerebral vascular disease. Diabetes Res Clin Pract. 1994;24(Suppl.):S205-8. doi: http://dx.doi.org/10.1016/0168-8227(94)90250-X
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol. 2006;5:64-74. doi: http://dx.doi.org/10.1016/S1474-4422(05)70284-2
Biessels GJ, Kappelle LJ. Increased risk of Alzheimer’s disease in type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33:1041-4. doi: http://dx.doi.org/10.1042/BST20051041
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329-44. doi: http://dx.doi.org/10.1056/NEJMra0909142
Craft S, Watson GS. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol. 2004;3:169-78. doi: http://dx.doi.org/10.1016/S1474-4422(04)00681-7
Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer’s disease. Trends Neurosci. 1995;18:172-6. doi: http://dx.doi.org/10.1016/0166-2236(95)93897-7
Irie F, Fitzpatrick AL, López OL, Kuller LH, Peila R, Newman AB, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol. 2008;65:89-93. doi: http://dx.doi.org/10.1001/archneurol.2007.29
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. doi: http://dx.doi.org/10.1093/nar/16.3.1215
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-8. PMid:2341813
Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, et al. Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 2011;21:691-724.
Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Santamato A, et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol. 2008;7:812-26. doi: http://dx.doi.org/10.1016/S1474-4422(08)70169-8
Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Arch Neurol. 2003;60:223-8. doi: http://dx.doi.org/10.1001/archneur.60.2.223
Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke. 2003;34:594-9. doi: http://dx.doi.org/10.1161/01.STR.0000060127.96986.F4
Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7:108-14. doi: http://dx.doi.org/10.1038/nrendo.2010.228
Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome Vs. Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-50. doi: http://dx.doi.org/10.1001/archinte.165.22.2644
Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Arch Neurol. 2011;68:1245-51. doi: http://dx.doi.org/10.1001/archneurol.2011.146
Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: The Rotterdam Study. Lancet. 1998;351:1840-3. doi: http://dx.doi.org/10.1016/S0140-6736(97)07541-7
Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C. Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008;8:36. doi: http://dx.doi.org/10.1186/1471-2318-8-36
Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM. Relation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study. Neurology. 2007;69:998-1005. doi: http://dx.doi.org/10.1212/01.wnl.0000271395.29695.9a
Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367-78. doi: http://dx.doi.org/10.1093/aje/kwm116
Debanne SM, Rowland DY, Riedel TM, Cleves MA. Association of Alzheimer’s disease and smoking: The case for sibling controls. J Am Geriatr Soc. 2000;48:800-6. PMid:10894320
Doll R, Peto R, Boreham J, Sutherland I. Smoking and dementia in male British doctors: Prospective study. BMJ. 2000;320:1097-102. doi: http://dx.doi.org/10.1136/bmj.320.7242.1097
Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit H. Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare. Neurology. 2002;58:62-70. doi: http://dx.doi.org/10.1212/WNL.58.1.62
Algunos artículos similares:
- Juan Carlos Miguel, Ariana Erazo, Fernanda Beduino, Juan Carlos Picena, María Isabel Luciano, Gustavo Pizzuti, María Cristina Tarrés, Silvana Montenegro, Stella Maris Martínez, Dilataciones bronquiales crónicas en diferentes colonias de ratas de laboratorio , Biomédica: Vol. 22 Núm. 2 (2002)
- María Lilia Díaz, Sulma Muñoz, Liz Betty Garcíad, Tuberculosis en el Hospital Universitario San José, Popayán, 1998-2000. , Biomédica: Vol. 24 (2004): Suplemento 1
- Margarita Giraldo-Chica, Natalia Acosta-Baena, Lorena Urbano, Lina Velilla, Francisco Lopera, Nicolás Pineda, Nueva mutación para xantomatosis cerebrotendinosa causa demencia familiar temprana en Colombia , Biomédica: Vol. 35 Núm. 4 (2015)
- Alejandra Saldarriaga-Cantillo, Viviana Yepes-Gaviria, Juan Carlos Rivas, Hidrocefalia de presión normal: demora en el diagnóstico , Biomédica: Vol. 40 Núm. 4 (2020)
- Silvia Martínez , Bárbara Ochoa , María Rafaela Pérez , Fátima Torrico , Ildemaro García , Carmen Cristina Garcia, Polimorfismos del gen de la apolipoproteína E en adultos mayores de 60 años con disminución de la memoria cognitiva y enfermedad de Alzheimer en diferentes poblaciones venezolanas , Biomédica: Vol. 42 Núm. Sp. 1 (2022): Mayo, Enfermedades crónicas en el trópico
- Jairo Lizarazo, Aixa Xiomara Vargas, Rafael Olarte, David Andrés Lizarazo, Determinación de priones en el diagnóstico de la enfermedad de Creutzfeldt-Jakob: un reporte de caso en el nororiente colombiano , Biomédica: Vol. 44 Núm. 4 (2024)
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
